A high prevalence of EGFR and ALK mutations was found in the lung adenocarcinoma of non-smokers with better survivals, which may benefit from the invention of suitable target therapies, and suggested different oncogenic mechanisms of the cancer itself that call for further investigations (40). This evidence concerns the gene EGFR and cancer.